As AP-1 can be activated by IL-1, targeting IL-1 could be beneficial for oral cancer treatment, as this could reduce the activation of NF-κB and AP-1 pathways with subsequent reduction of bcl-2, but this hypothesis needs to be corroborated. The gene discussed is IL1B; the disease is lip and oral cavity carcinoma.